Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An Author's Perspective
    • Ask the Experts
    • Bioanalysis articles
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Spotlights
    • Tech Digest
    • T&F journals

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Awareness
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Professional development
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • Jessica Bridges Weaver named as a 2026 Women in Business award winner
  • Stretching the limit: new technique improves measurement of cell elasticity
  • Highlights from the 20th WRIB

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

7 FEB 2016 JOURNAL ARTICLES
Highly specific and sensitive immunoassay for the measurement of prostaglandin E2 in biological fluids
Microfluidic, microdroplet
9 FEB 2024 NEWS
New microfluidic platform increases microdroplet formation rate
1 APR 2011 CLINICAL
Bioanalytical interferences in immunoassays for antibody biotherapeutics
15 MAY 2014 GENERAL INTEREST
Electric nose could be used to detect prostate cancer by smell
3 OCT 2013 GENERAL INTEREST
Watch the AB SCIEX Pharma & Biologics Webinar Series from August 21-December 4, 2013
16 APR 2026 AN AUTHOR'S PERSPECTIVE
An author’s perspective: Early pre-existing ADA screening in biotherapeutic development
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Permissions
  • Whitelist Emails
  • Zone Leaders

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone